Pneumagen logo.jpg
Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 Conference
May 23, 2024 07:00 ET | Pneumagen Ltd
 Neumifil delivers statistically significant reductions in influenza symptomatic infection rate, symptom severity and viral loadStrategy to advance clinical development of Neumifil to be based on...
Pneumagen logo.jpg
Pneumagen to Present Phase 2 Clinical Data on Neumifil, its Broad-Spectrum Antiviral, Intranasal Drug for Viral Respiratory Tract Infections, at ATS 2024
May 02, 2024 07:00 ET | Pneumagen Ltd
Data to be presented in oral and ePoster presentations St Andrews, UK – 2 May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for...
Pneumagen logo.jpg
Pneumagen Announces Successful Clinical Proof of Concept for its Broad-Spectrum Antiviral Neumifil in Phase 2 Influenza Human Challenge Study
October 02, 2023 04:00 ET | Pneumagen Ltd
Study achieves primary & secondary endpoints in a randomised, placebo-controlled challenge studyNeumifil delivers a statistically significant reduction in both symptomatic infection rate &...
Pneumagen logo.jpg
Pneumagen raises £8m to accelerate Phase 2 clinical development of Neumifil for the prevention & treatment of viral respiratory tract infections
June 01, 2023 04:00 ET | Pneumagen Ltd
Neumifil is being developed for the prevention and treatment of virus induced exacerbations in patients with respiratory diseaseAdvancing Neumifil into a Phase 2b clinical study due to start in 2024 ...
Pneumagen logo.jpg
Pneumagen further strengthens IP protection for lead product Neumifil with granting of US composition of matter patent
April 18, 2023 04:00 ET | Pneumagen Ltd
Neumifil is a novel intranasal spray being developed to provide those at-risk with an easy to use, broad-spectrum antiviral treatment to reduce and prevent respiratory disease exacerbations caused by...